Which hormone replacement therapy regimens are safe for a patient with a known meningioma?

Hormone Replacement Therapy Safety in Meningioma

Estrogen-only HRT appears safe for patients with known meningioma, while all progestin-containing regimens should be strictly avoided.

Key Recommendation

The critical distinction is between estrogen-based and progestin-based therapies. Based on the available evidence, here's the algorithmic approach:

Safe HRT Options:

• Estrogen-only therapy (transdermal preferred): Recent data suggests this may actually be protective rather than harmful 1
  • A 2020 study found that estrogen-HRT was associated with 35% smaller tumor diameter and half the growth rate compared to no-HRT controls 1
  • Radiographic progression-free survival was 1.2 years longer with estrogen-HRT 1

Contraindicated HRT Options:

• All progestin-containing regimens must be avoided, including:
  • Combined estrogen-progestagen therapy
  • Progestagen-only therapy
  • Cyproterone acetate (CPA) - shows dose-dependent relationship with meningioma incidence and growth 2
  • Chlormadinone acetate and nomegestrol acetate 2
  • Megestrol acetate - case reports show tumor regression after cessation 3

Evidence Analysis

The progestin risk is well-established: Long-term combined estrogen-progestagen therapy (≥10 years) increases meningioma risk with an OR of 2.2, rising to 2.7 when used as sole therapy 4. High-dose CPA shows an OR of 6.30 for meningioma development 5. CPA-associated meningiomas are characteristically multiple, located in anterior/middle skull base, and may harbor PIK3CA mutations 2.

The estrogen data is reassuring: While one 2013 Danish study suggested long-term HRT increased risk (OR 1.3 for ever-use) 4, the most recent 2020 growth-rate analysis directly contradicts concerns about estrogen monotherapy, showing slower growth and longer progression-free survival 1. The 2022 review acknowledges conflicting epidemiological data but notes a recent study failed to show increased meningioma growth in HRT-treated patients 2.

Guideline perspective: The 2025 EANO guideline notes that while 76% of meningiomas express progesterone receptors, testing for PR/ER expression to guide antihormonal treatment is discouraged outside clinical trials (ESCAT IVA) 6. However, this addresses treatment of existing meningiomas, not HRT safety.

Clinical Algorithm

For patients with known meningioma requiring HRT:

1. Immediately discontinue any progestin-containing therapy if currently prescribed
2. Consider estrogen-only HRT if menopausal symptoms require treatment:
   • Prefer transdermal over oral formulations (avoids first-pass hepatic effects)
   • Start with lowest effective dose
   • Establish baseline MRI before initiating therapy
3. Implement surveillance protocol:
   • MRI at 3-6 months after HRT initiation
   • If stable, continue annual MRI surveillance
   • Any growth >2mm should prompt HRT discontinuation and neurosurgical consultation

Important Caveats

• Oral contraceptives: Current evidence does not support increased meningioma risk with standard oral contraceptive use 2, 5
• Fertility treatments: Insufficient data to make definitive recommendations 2
• Male patients: Androgen analogues show significantly increased risk (OR 19.09), though based on limited cases 5

The bottom line: If HRT is medically necessary for a patient with meningioma, estrogen-only therapy with close radiographic monitoring is a reasonable option, while any progestin exposure should be considered an absolute contraindication given the established dose-dependent relationship with tumor growth.